Pfizer Unsuccessful in Avoiding Off-Label Marketing False Claims Act Case

Pfizer is allegedly continuing its practice of fraudulent marketing tactics for its antipsychotic schizophrenia drug Geodon despite settling with the government on this matter in 2009 for $2.3 billion. At that time, Pfizer was allegedly touting Geodon for unapproved uses, including post-traumatic stress disorder, anxiety and autism. Image source: In a recent [...]

By | 2018-03-27T09:00:50+00:00 April 25th, 2014|Healthcare Fraud|